I earned my Bachelor of Science in Brain and Cognitive Sciences at the Massachusetts Institute of Technology, where I conducted research within the Early Childhood Cognition Laboratory. I completed my MD and PhD in Experimental and Molecular Medicine within the Neuroscience Track as part of the MD-PhD Program at Dartmouth Medical School. My dissertation research examined the effects of cannabis administration on clinical, neuropsychological, and brain circuit functioning in individuals with schizophrenia and cannabis use disorder. I then joined the Research Track Psychiatry Residency at Stanford, where I am currently in my final year of clinical training and a T32 NIMH funded post-doctoral research fellow. While at Stanford, I have cultivated my clinical expertise in understanding and treating youth struggling with co-occurring depressive and substance use disorders. With the mentorship of Drs. Manpreet Singh, Alan Schatzberg, and Ian Gotlib, I focused my post-graduate research on (1) defining neural circuitry biomarkers of risk and resilience in adolescents at high and low familial risk for depression, (2) examining the clinical applicability of functional neuroimaging in depression to develop improved treatment interventions, and (3) applying predictive modeling to determine whether adolescents at high familial risk will experience depression or remain resilient. My long-term goal is to be a leader in the prevention and treatment of co-occurring depressive and substance use disorders in adolescence and young adulthood. To this end, my career goals include overseeing a ‘dual’ disorders clinic for adolescents and transitional age youth, and running a translational laboratory investigating the neurobiological and neurodevelopmental mechanisms of co-occurring depressive and substance use disorders in order to develop evidence-based, neurobiologically informed treatments.